2020 Annual Meeting of Stockholders
For Fiscal Year Ending Dec 31, 2019
Receive updates straight into your inbox
Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system conditions. The Company has four novel and differentiated investigational drug candidates, including IV oliceridine, for the management of moderate to severe acute pain in hospitals, TRV250 for the acute treatment of migraine, and TRV734 for maintenance treatment of opioid use disorder. The Company has also identified TRV045, a novel S1P receptor modulator that may offer a new, non-opioid approach to managing chronic pain.
955 Chesterbrook Blvd Suite 110 Chesterbrook, PA 19087
T: (610) 354-8840
LifeSci Advisors, LLC Dan Ferry Managing Director T: 617-430-7576 firstname.lastname@example.org